Get the Stockscreener App
22.71
5.82%
1.25
Pre-market:
22.58
-0.13
-0.57%
Enovis Corp stock is traded at $22.71, with a volume of 1.62M.
It is up +5.82% in the last 24 hours and down -16.14% over the past month.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
See More
Previous Close:
$21.46
Open:
$21.45
24h Volume:
1.62M
Relative Volume:
1.75
Market Cap:
$1.30B
Revenue:
$2.19B
Net Income/Loss:
$-829.17M
P/E Ratio:
-1.5937
EPS:
-14.25
Net Cash Flow:
$-3.95M
1W Performance:
-3.57%
1M Performance:
-16.14%
6M Performance:
-16.87%
1Y Performance:
-52.06%
1-Day Range:
$21.00
$22.74
1-Week Range:
$21.00
$23.43
52-Week Range:
$21.00
$48.37
Enovis Corp Stock (ENOV) Company Profile
Name
Enovis Corp
Sector
Industry
Phone
(302) 252-9160
Address
2711 CENTERVILLE ROAD, WILMINGTON
Compare ENOV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENOV
Enovis Corp
|
22.71 | 1.23B | 2.19B | -829.17M | -3.95M | -14.25 |
|
ABT
Abbott Laboratories
|
106.09 | 184.41B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
92.33 | 139.09B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.30 | 136.84B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.00 | 129.21B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
81.49 | 47.50B | 5.88B | 1.34B | 799.60M | 2.3489 |
Enovis Corp Stock (ENOV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Initiated | BTIG Research | Buy |
| Oct-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Jun-13-24 | Initiated | JP Morgan | Neutral |
| Feb-13-24 | Initiated | Stephens | Overweight |
| Jan-22-24 | Initiated | UBS | Buy |
| Jan-03-24 | Initiated | William Blair | Outperform |
| Dec-15-23 | Reiterated | Needham | Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Jun-26-23 | Initiated | Needham | Buy |
| May-12-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-11-22 | Initiated | Goldman | Buy |
| Sep-12-22 | Initiated | Canaccord Genuity | Buy |
| Sep-12-22 | Initiated | Evercore ISI | Outperform |
| Jun-28-22 | Initiated | Argus | Hold |
| Jun-27-22 | Resumed | Loop Capital | Buy |
| Jun-16-22 | Initiated | Wells Fargo | Equal Weight |
View All
Enovis Corp Stock (ENOV) Latest News
Can Enovis Corporation lead its sector in growthEarnings Summary Report & Weekly Setup with High ROI Potential - mfd.ru
Risk Recap: Is Enovis Corporation stock a good dividend stockJuly 2025 Price Swings & Safe Swing Trade Setups - baoquankhu1.vn
Enovis Corp (ENOV) Trading Down 3.36% on Jan 28 - GuruFocus
Analysts Have Conflicting Sentiments on These Healthcare Companies: Enovis (ENOV), Guardian Pharmacy Services, Inc. Class A (GRDN) and Biogen (BIIB) - The Globe and Mail
Enovis Corporation (ENOV) Stock Analysis: Exploring a Healthcare Investment with 100% Upside Potential - DirectorsTalk Interviews
Enovis (NYSE:ENOV) Hits New 52-Week LowTime to Sell? - MarketBeat
Investment Recap: What are Enovis Corporation’s technical support levels2025 Sector Review & Trade Opportunity Analysis - baoquankhu1.vn
Ideas Watch: Is Armstrong World Industries Inc. forming higher highs and higher lowsMarket Performance Report & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Enovis stock hits 52-week low at $22.93 amid challenging year - Investing.com Australia
Enovis stock hits 52-week low at $22.93 amid challenging year By Investing.com - Investing.com South Africa
Enovis Corp (ENOV) Shares Down 3.93% on Jan 23 - GuruFocus
Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Call on February 26th - The Globe and Mail
Is Enovis’ LimaCorporate Integration And Margin Push Rewriting The Investment Case For ENOV? - Yahoo Finance
Enovis Corporation (ENOV): Orthopedic Innovation and Growth Potential Drive Analyst Confidence - Insider Monkey
Assessing Enovis (ENOV) Valuation After Recent Weak Share Price Performance - simplywall.st
Oliver Engert: First Chief Administrative Officer at Enovis - Orthopedics This Week
Top 3 Health Care Stocks That Could Blast Off This Month - Benzinga
Enovis Corporation $ENOV Shares Sold by Stephens Inc. AR - MarketBeat
Levels Update: How does Empire State Realty Trust Inc score in quality rankingsJuly 2025 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn
Enovis (NYSE:ENOV) Hits New 1-Year LowHere's Why - MarketBeat
Enovis Corporation (ENOV): A Bull Case Theory - Finviz
Is Enovis Corporation undervalued by DCF analysisPrice Action & Precise Swing Trade Entry Alerts - bollywoodhelpline.com
Can Enovis Corporation beat the S P 5002025 Historical Comparison & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Aug Big Picture: Will DT Cloud Acquisition Corporation benefit from seasonality2025 Market Sentiment & Real-Time Volume Surge Alerts - baoquankhu1.vn
Stock Market Recap: Is Enovis Corporation part of any ETFWatch List & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Support Test: Is HUBC stock showing strong momentumPortfolio Performance Summary & Weekly Breakout Watchlists - baoquankhu1.vn
March 20th Options Now Available For Enovis (ENOV) - Nasdaq
A Look At Enovis (ENOV) Valuation After Naming Oliver Engert As Chief Administrative Officer - Sahm
Enovis stock hits 52-week low at 25.43 USD By Investing.com - Investing.com Canada
Enovis Names Davide Visentin as President of International Surgical Division - MSN
William Blair Maintains Enovis Corp(ENOV.US) With Buy Rating - 富途牛牛
Enovis stock hits 52-week low at 25.43 USD - Investing.com
Enovis (NYSE:ENOV) Releases FY 2025 Earnings Guidance - MarketBeat
BTIG Maintains Enovis Corp(ENOV.US) With Buy Rating, Maintains Target Price $41 - 富途资讯
Evercore Maintains Enovis Corp(ENOV.US) With Buy Rating, Maintains Target Price $40 - 富途资讯
Enovis (NYSE:ENOV) Trading Down 7.3%Time to Sell? - MarketBeat
Enovis free cash flow set to improve in FY26, says Evercore ISI - TipRanks
How a Medical Device Company Uses Financial Instruments to Support Its Strategy - Citizens Bank
ENOV Earnings Expectations: Consensus Estimate Stands at $3.18 - GuruFocus
Enovis (ENOV) Surpasses EPS Expectations in Q4, Cash Flow Set to Improve - GuruFocus
Enovis (ENOV) Projects 50bps aEBITDA Expansion by 2026 - GuruFocus
Enovis Lowers Top End of 2025 Revenue Guidance - 富途资讯
Enovis to Present at J.P. Morgan Healthcare Conference - TipRanks
Is Enovis (ENOV) Elevating Execution Risk Management With Its New Chief Administrative Officer? - simplywall.st
Will Enovis Corporation stock attract more institutional investors2025 Top Gainers & Risk Controlled Stock Alerts - Улправда
Why Enovis Corporation stock could see breakout soon2025 Support & Resistance & Consistent Profit Trading Strategies - Улправда
Will Enovis Corporation stock outperform Nasdaq index2025 Earnings Impact & Real-Time Volume Analysis - ulpravda.ru
Why Enovis Corporation stock is in analyst buy zone2025 Bull vs Bear & Long-Term Safe Investment Ideas - Улправда
Is Enovis Corporation stock positioned for secular growthStop Loss & Reliable Volume Spike Alerts - Улправда
Why Enovis Corporation stock remains on watchlistsCEO Change & Community Consensus Picks - ulpravda.ru
Tributary Capital Management LLC Acquires 551,613 Shares of Enovis Corporation $ENOV - MarketBeat
Enovis Corp Stock (ENOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):